Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Hematogenous extramedullary relapse in multiple myeloma - a multicenter retrospective study in 127 patients.

Avivi I, Cohen YC, Suska A, Shragai T, Mikala G, Garderet L, Seny GM, Glickman S, Jayabalan DS, Niesvizky R, Gozzetti A, Wiśniewska-Piąty K, Waszczuk-Gajda A, Usnarska-Zubkiewicz L, Hus I, Guzicka R, Radocha J, Milunovic V, Davila J, Gentile M, Castillo JJ, Jurczyszyn A.

Am J Hematol. 2019 Oct;94(10):1132-1140. doi: 10.1002/ajh.25579. Epub 2019 Aug 13.

PMID:
31334859
2.

Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma.

Mark TM, Forsberg PA, Rossi AC, Pearse RN, Pekle KA, Perry A, Boyer A, Tegnestam L, Jayabalan D, Coleman M, Niesvizky R.

Blood Adv. 2019 Feb 26;3(4):603-611. doi: 10.1182/bloodadvances.2018028027.

3.

Phase II study of carfilzomib and dexamethasone therapy for newly diagnosed multiple myeloma.

Forsberg PA, Rossi AC, Boyer A, Tegnestam L, Pearse RN, Perry A, Pekle KA, Jayabalan D, Ely S, Boussi L, Sherbenou DW, Williams C, Allan JN, Coleman M, Niesvizky R, Mark TM.

Am J Hematol. 2019 May;94(5):539-545. doi: 10.1002/ajh.25435. Epub 2019 Feb 25.

PMID:
30740766
4.

Cellular proliferation by multiplex immunohistochemistry identifies aggressive disease behavior in relapsed multiple myeloma.

Forsberg PA, Hammes A, Abbott D, Sherbenou DW, Rossi A, Jayabalan D, Niesvizky R, Mark TM, Ely S.

Leuk Lymphoma. 2019 Aug;60(8):2085-2087. doi: 10.1080/10428194.2018.1551537. Epub 2019 Jan 11. No abstract available.

PMID:
30632821
5.

Multiple myeloma in patients up to 30 years of age: a multicenter retrospective study of 52 cases.

Jurczyszyn A, Davila J, Kortüm KM, Jayabalan DS, Vij R, Fiala M, Milunovic V, Chim CS, Wiśniewska-Piąty K, Waszczuk-Gajda A, Crusoe E, Hajek R, Robak P, Raźny M, Zawirska D, Bittrich M, Nahi H, Liu J, Castillo JJ, Vesole DH.

Leuk Lymphoma. 2019 Feb;60(2):471-476. doi: 10.1080/10428194.2018.1480766. Epub 2018 Jul 22.

PMID:
30033832
6.

Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients.

Jurczyszyn A, Castillo JJ, Avivi I, Czepiel J, Davila J, Vij R, Fiala MA, Gozzetti A, Grząśko N, Milunovic V, Hus I, Mądry K, Waszczuk-Gajda A, Usnarska-Zubkiewicz L, Dębski J, Atilla E, Beksac M, Mele G, Sawicki W, Jayabalan D, Charliński G, Gyula Szabo A, Hajek R, Delforge M, Kopacz A, Fantl D, Waage A, Crusoe E, Hungria V, Richardson P, Laubach J, Guerrero-Garcia T, Liu J, Vesole DH.

Leuk Lymphoma. 2019 Jan;60(1):118-123. doi: 10.1080/10428194.2018.1473574. Epub 2018 Jul 2.

PMID:
29965787
7.

Germline Lysine-Specific Demethylase 1 (LSD1/KDM1A) Mutations Confer Susceptibility to Multiple Myeloma.

Wei X, Calvo-Vidal MN, Chen S, Wu G, Revuelta MV, Sun J, Zhang J, Walsh MF, Nichols KE, Joseph V, Snyder C, Vachon CM, McKay JD, Wang SP, Jayabalan DS, Jacobs LM, Becirovic D, Waller RG, Artomov M, Viale A, Patel J, Phillip J, Chen-Kiang S, Curtin K, Salama M, Atanackovic D, Niesvizky R, Landgren O, Slager SL, Godley LA, Churpek J, Garber JE, Anderson KC, Daly MJ, Roeder RG, Dumontet C, Lynch HT, Mullighan CG, Camp NJ, Offit K, Klein RJ, Yu H, Cerchietti L, Lipkin SM.

Cancer Res. 2018 May 15;78(10):2747-2759. doi: 10.1158/0008-5472.CAN-17-1900. Epub 2018 Mar 20.

8.

Novel pedigree analysis implicates DNA repair and chromatin remodeling in multiple myeloma risk.

Waller RG, Darlington TM, Wei X, Madsen MJ, Thomas A, Curtin K, Coon H, Rajamanickam V, Musinsky J, Jayabalan D, Atanackovic D, Rajkumar SV, Kumar S, Slager S, Middha M, Galia P, Demangel D, Salama M, Joseph V, McKay J, Offit K, Klein RJ, Lipkin SM, Dumontet C, Vachon CM, Camp NJ.

PLoS Genet. 2018 Feb 1;14(2):e1007111. doi: 10.1371/journal.pgen.1007111. eCollection 2018 Feb.

9.

Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients.

Jurczyszyn A, Radocha J, Davila J, Fiala MA, Gozzetti A, Grząśko N, Robak P, Hus I, Waszczuk-Gajda A, Guzicka-Kazimierczak R, Atilla E, Mele G, Sawicki W, Jayabalan DS, Charliński G, Szabo AG, Hajek R, Delforge M, Kopacz A, Fantl D, Waage A, Avivi I, Rodzaj M, Leleu X, Richez V, Knopińska-Posłuszny W, Masternak A, Yee AJ, Barchnicka A, Druzd-Sitek A, Guerrero-Garcia T, Liu J, Vesole DH, Castillo JJ.

Br J Haematol. 2018 Mar;180(6):831-839. doi: 10.1111/bjh.15092. Epub 2018 Jan 7.

PMID:
29315478
10.

Cellular Proliferation by Multiplex Immunohistochemistry Identifies High-Risk Multiple Myeloma in Newly Diagnosed, Treatment-Naive Patients.

Ely S, Forsberg P, Ouansafi I, Rossi A, Modin A, Pearse R, Pekle K, Perry A, Coleman M, Jayabalan D, Di Liberto M, Chen-Kiang S, Niesvizky R, Mark TM.

Clin Lymphoma Myeloma Leuk. 2017 Dec;17(12):825-833. doi: 10.1016/j.clml.2017.09.010. Epub 2017 Sep 20.

PMID:
29051077
11.

Bacteriocins as food preservatives: Challenges and emerging horizons.

Johnson EM, Jung DY, Jin DY, Jayabalan DR, Yang DSH, Suh JW.

Crit Rev Food Sci Nutr. 2018;58(16):2743-2767. doi: 10.1080/10408398.2017.1340870. Epub 2017 Sep 7. Review.

PMID:
28880573
12.

Identification of a nucleoside analog active against adenosine kinase-expressing plasma cell malignancies.

Nayar U, Sadek J, Reichel J, Hernandez-Hopkins D, Akar G, Barelli PJ, Sahai MA, Zhou H, Totonchy J, Jayabalan D, Niesvizky R, Guasparri I, Hassane D, Liu Y, Sei S, Shoemaker RH, Warren JD, Elemento O, Kaye KM, Cesarman E.

J Clin Invest. 2017 Jun 1;127(6):2066-2080. doi: 10.1172/JCI83936. Epub 2017 May 15.

13.

IgM myeloma: A multicenter retrospective study of 134 patients.

Castillo JJ, Jurczyszyn A, Brozova L, Crusoe E, Czepiel J, Davila J, Dispenzieri A, Eveillard M, Fiala MA, Ghobrial IM, Gozzetti A, Gustine JN, Hajek R, Hungria V, Jarkovsky J, Jayabalan D, Laubach JP, Lewicka B, Maisnar V, Manasanch EE, Moreau P, Morgan EA, Nahi H, Niesvizky R, Paba-Prada C, Pika T, Pour L, Reagan JL, Richardson PG, Shah J, Spicka I, Vij R, Waszczuk-Gajda A, Gertz MA.

Am J Hematol. 2017 Aug;92(8):746-751. doi: 10.1002/ajh.24753. Epub 2017 May 26.

14.

A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma.

Mark TM, Guarneri D, Forsberg P, Rossi A, Pearse R, Perry A, Pekle K, Tegnestam L, Greenberg J, Shore T, Gergis U, Mayer S, Van Besien K, Ely S, Jayabalan D, Sherbenou D, Coleman M, Niesvizky R.

Biol Blood Marrow Transplant. 2017 Jun;23(6):930-937. doi: 10.1016/j.bbmt.2017.03.007. Epub 2017 Mar 8.

15.

Characteristics and outcomes of patients with multiple myeloma aged 21-40 years versus 41-60 years: a multi-institutional case-control study.

Jurczyszyn A, Nahi H, Avivi I, Gozzetti A, Niesvizky R, Yadlapati S, Jayabalan DS, Robak P, Pika T, Andersen KT, Rasche L, Mądry K, Woszczyk D, Raźny M, Usnarska-Zubkiewicz L, Knopińska-Posłuszny W, Wojciechowska M, Guzicka-Kazimierczak R, Joks M, Grosicki S, Ciepłuch H, Rymko M, Vesole DH, Castillo JJ.

Br J Haematol. 2016 Dec;175(5):884-891. doi: 10.1111/bjh.14328. Epub 2016 Sep 29.

PMID:
27682187
16.

Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.

Niesvizky R, Badros AZ, Costa LJ, Ely SA, Singhal SB, Stadtmauer EA, Haideri NA, Yacoub A, Hess G, Lentzsch S, Spicka I, Chanan-Khan AA, Raab MS, Tarantolo S, Vij R, Zonder JA, Huang X, Jayabalan D, Di Liberto M, Huang X, Jiang Y, Kim ST, Randolph S, Chen-Kiang S.

Leuk Lymphoma. 2015;56(12):3320-8. doi: 10.3109/10428194.2015.1030641. Epub 2015 May 15.

PMID:
25813205
17.

Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma.

Mark TM, Bowman IA, Rossi AC, Shah M, Rodriguez M, Quinn R, Pearse RN, Zafar F, Pekle K, Jayabalan D, Ely S, Coleman M, Chen-Kiang S, Niesvizky R.

Leuk Lymphoma. 2014 Dec;55(12):2842-9. doi: 10.3109/10428194.2014.896005. Epub 2014 Mar 25.

PMID:
24576165
18.

IgG4 plasma cell myeloma: new insights into the pathogenesis of IgG4-related disease.

Geyer JT, Niesvizky R, Jayabalan DS, Mathew S, Subramaniyam S, Geyer AI, Orazi A, Ely SA.

Mod Pathol. 2014 Mar;27(3):375-81. doi: 10.1038/modpathol.2013.159. Epub 2013 Sep 13.

19.

Overcoming the response plateau in multiple myeloma: a novel bortezomib-based strategy for secondary induction and high-yield CD34+ stem cell mobilization.

Niesvizky R, Mark TM, Ward M, Jayabalan DS, Pearse RN, Manco M, Stern J, Christos PJ, Mathews L, Shore TB, Zafar F, Pekle K, Xiang Z, Ely S, Skerret D, Chen-Kiang S, Coleman M, Lane ME.

Clin Cancer Res. 2013 Mar 15;19(6):1534-46. doi: 10.1158/1078-0432.CCR-12-1429. Epub 2013 Jan 28.

20.

BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma.

Rossi A, Mark T, Jayabalan D, Christos P, Zafar F, Pekle K, Pearse R, Chen-Kiang S, Coleman M, Niesvizky R.

Blood. 2013 Mar 14;121(11):1982-5. doi: 10.1182/blood-2012-08-448563. Epub 2013 Jan 8.

21.

Prolonged early G(1) arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4.

Huang X, Di Liberto M, Jayabalan D, Liang J, Ely S, Bretz J, Shaffer AL 3rd, Louie T, Chen I, Randolph S, Hahn WC, Staudt LM, Niesvizky R, Moore MA, Chen-Kiang S.

Blood. 2012 Aug 2;120(5):1095-106. doi: 10.1182/blood-2012-03-415984. Epub 2012 Jun 20.

22.

MAGE-A inhibits apoptosis in proliferating myeloma cells through repression of Bax and maintenance of survivin.

Nardiello T, Jungbluth AA, Mei A, Diliberto M, Huang X, Dabrowski A, Andrade VC, Wasserstrum R, Ely S, Niesvizky R, Pearse R, Coleman M, Jayabalan DS, Bhardwaj N, Old LJ, Chen-Kiang S, Cho HJ.

Clin Cancer Res. 2011 Jul 1;17(13):4309-19. doi: 10.1158/1078-0432.CCR-10-1820. Epub 2011 May 12.

23.

Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma.

Gay F, Rajkumar SV, Coleman M, Kumar S, Mark T, Dispenzieri A, Pearse R, Gertz MA, Leonard J, Lacy MQ, Chen-Kiang S, Roy V, Jayabalan DS, Lust JA, Witzig TE, Fonseca R, Kyle RA, Greipp PR, Stewart AK, Niesvizky R.

Am J Hematol. 2010 Sep;85(9):664-9. doi: 10.1002/ajh.21777.

24.

Cellular immune responses against CT7 (MAGE-C1) and humoral responses against other cancer-testis antigens in multiple myeloma patients.

Lendvai N, Gnjatic S, Ritter E, Mangone M, Austin W, Reyner K, Jayabalan D, Niesvizky R, Jagannath S, Bhardwaj N, Chen-Kiang S, Old LJ, Cho HJ.

Cancer Immun. 2010 Jan 29;10:4.

25.

CDK2 phosphorylation of Smad2 disrupts TGF-beta transcriptional regulation in resistant primary bone marrow myeloma cells.

Baughn LB, Di Liberto M, Niesvizky R, Cho HJ, Jayabalan D, Lane J, Liu F, Chen-Kiang S.

J Immunol. 2009 Feb 15;182(4):1810-7. doi: 10.4049/jimmunol.0713726.

26.

Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma.

Mark T, Jayabalan D, Coleman M, Pearse RN, Wang YL, Lent R, Christos PJ, Lee JW, Agrawal YP, Matthew S, Ely S, Mazumdar M, Cesarman E, Leonard JP, Furman RR, Chen-Kiang S, Niesvizky R.

Br J Haematol. 2008 Dec;143(5):654-60. doi: 10.1111/j.1365-2141.2008.07374.x. Epub 2008 Oct 16.

27.

Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma.

Mark T, Stern J, Furst JR, Jayabalan D, Zafar F, LaRow A, Pearse RN, Harpel J, Shore T, Schuster MW, Leonard JP, Christos PJ, Coleman M, Niesvizky R.

Biol Blood Marrow Transplant. 2008 Jul;14(7):795-8. doi: 10.1016/j.bbmt.2008.04.008.

28.

The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of ixabepilone: a first in class epothilone B analogue in late-phase clinical development.

Goel S, Cohen M, Cömezoglu SN, Perrin L, André F, Jayabalan D, Iacono L, Comprelli A, Ly VT, Zhang D, Xu C, Humphreys WG, McDaid H, Goldberg G, Horwitz SB, Mani S.

Clin Cancer Res. 2008 May 1;14(9):2701-9. doi: 10.1158/1078-0432.CCR-07-4151.

29.

Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma.

Niesvizky R, Martínez-Baños D, Jalbrzikowski J, Christos P, Furst J, De Sancho M, Mark T, Pearse R, Mazumdar M, Zafar F, Pekle K, Leonard J, Jayabalan D, Coleman M.

Leuk Lymphoma. 2007 Dec;48(12):2330-7.

PMID:
18067007
30.

BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.

Niesvizky R, Jayabalan DS, Christos PJ, Furst JR, Naib T, Ely S, Jalbrzikowski J, Pearse RN, Zafar F, Pekle K, Larow A, Lent R, Mark T, Cho HJ, Shore T, Tepler J, Harpel J, Schuster MW, Mathew S, Leonard JP, Mazumdar M, Chen-Kiang S, Coleman M.

Blood. 2008 Feb 1;111(3):1101-9. Epub 2007 Nov 7.

PMID:
17989313
31.

Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy.

Niesvizky R, Naib T, Christos PJ, Jayabalan D, Furst JR, Jalbrzikowski J, Zafar F, Mark T, Lent R, Pearse RN, Ely S, Leonard JP, Mazumdar M, Chen-Kiang S, Coleman M.

Br J Haematol. 2007 Sep;138(5):640-3.

PMID:
17686058
32.

The adipocyte as an important target cell for Trypanosoma cruzi infection.

Combs TP, Nagajyothi, Mukherjee S, de Almeida CJ, Jelicks LA, Schubert W, Lin Y, Jayabalan DS, Zhao D, Braunstein VL, Landskroner-Eiger S, Cordero A, Factor SM, Weiss LM, Lisanti MP, Tanowitz HB, Scherer PE.

J Biol Chem. 2005 Jun 24;280(25):24085-94. Epub 2005 Apr 18.

Supplemental Content

Loading ...
Support Center